New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2014
07:37 EDTRGDORegado Biosciences' REG1 anticoagulant shows positive Phase 2b results
Regado Biosciences announced additional findings from its completed Phase 2b RADAR trial demonstrating the safety of early sheath removal in patients treated with REG1. The analysis showed that REG1 allowed for very early arterial sheath removal following cardiac catheterization without increasing the time to hemostasis or the frequency of vascular access-site bleeding complications. The study further determined that patients anticoagulated with REG1 during cardiac catheterization had their arterial sheath removed an average of more than three hours earlier than those anticoagulated with unfractionated heparin. Regado is currently testing REG1 in a global Phase 3 clinical trial, REGULATE-PCI, which is designed to show superiority in efficacy and non-inferiority in safety against the current standard, bivalirudin. The first of three key interim analyses in the trial is expected to occur during Q2.
News For RGDO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 10, 2014
07:31 EDTRGDORegado Biosciences appoints Michael Metzger CEO
Regado Biosciences announced the appointment of Michael Metzger, President of Regado, to the additional post of CEO and as a member of the board effective immediately. Metzger previously served as president and chief operating officer of Regado. He replaces David Mazzo, who has resigned from the company.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use